Global Pulmonary Embolism Drug Market Size By Type (DS-9231, DS-1040), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Pulmonary Embolism Drug Market was valued at USD 1.3 billion in 2023 and is expected to reach USD 2.6 billion by 2031, growing at a CAGR of 9.2% during the forecast period from 2023 to 2031. This growth is primarily driven by the rising prevalence of pulmonary embolism (PE), increasing awareness and diagnosis rates, and ongoing advancements in anticoagulant therapies. The market is witnessing a significant push from both the demand for effective oral anticoagulants and the launch of novel thrombolytic agents, particularly in high-risk patient groups.

Drivers:

1. Rising Incidence of Venous Thromboembolism (VTE):

A growing number of patients affected by VTE, including deep vein thrombosis (DVT) and PE, is fueling demand for therapeutic interventions. Sedentary lifestyles, aging populations, cancer, and post-surgical complications are contributing to this trend globally.

2. Preference for Oral Anticoagulants Over Warfarin:

Direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and edoxaban are gaining popularity due to their predictable pharmacokinetics and reduced need for regular monitoring, significantly improving patient compliance.

3. Technological and Clinical Advancements in PE Diagnosis and Treatment:

Enhanced imaging modalities and improved diagnostic criteria have led to more accurate and earlier detection of PE cases, subsequently increasing the treatment population.

Restraints:

1. Risk of Major Bleeding Events:

Despite their effectiveness, anticoagulant therapies carry the risk of internal bleeding, particularly in elderly or comorbid patients. This limits usage in certain populations and can hinder broader adoption.

2. High Cost of Novel Therapies:

While newer DOACs are more effective and convenient, their high price points limit accessibility in low-income and underinsured populations, particularly in emerging economies.

Opportunity:

1. Growing Adoption in Emerging Markets:

Healthcare infrastructure development and increased awareness campaigns in Asia-Pacific and Latin America are opening new avenues for market penetration of PE treatment drugs.

2. Pipeline Drugs and Personalized Treatment:

Ongoing clinical trials and the development of next-generation anticoagulants with targeted action and fewer side effects represent strong future opportunities.

3. Hospital-at-Home Models and Outpatient PE Treatment:

The expansion of outpatient care settings supported by DOACs has led to a significant opportunity to manage low-risk PE patients outside hospital environments, reducing costs and improving recovery outcomes.

Market by Drug Class Insights:

The Direct Oral Anticoagulants (DOACs) segment dominated the market in 2023. This segment is projected to remain the fastest-growing throughout the forecast period due to their simplified dosing, minimal drug-food interactions, and absence of routine coagulation monitoring compared to traditional therapies like warfarin.

Market by End-Use Insights:

In 2023, Hospitals accounted for the largest market share due to the immediate and acute management requirements of PE cases. However, the Ambulatory Surgical Centers (ASCs) and Homecare segments are poised for rapid growth, fueled by the adoption of oral medications that enable safe treatment beyond hospital walls.

Market by Regional Insights:

North America held the dominant share in 2023, attributed to advanced healthcare infrastructure, high awareness levels, and strong presence of pharmaceutical leaders. The Asia-Pacific region is expected to witness the highest CAGR, driven by the increasing prevalence of cardiovascular conditions, improving diagnostics, and expansion of healthcare access in countries like India and China.

Competitive Scenario:

Key market players include Bayer AG, Bristol-Myers Squibb, Pfizer Inc., Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Sanofi, and Aspen Pharmacare. These companies are actively investing in R&D, expanding their indications, and engaging in strategic partnerships to reinforce market presence.

Recent Developments:

In 2023, Bayer and Johnson & Johnson expanded the use of rivaroxaban (Xarelto) for long-term prevention of recurrent VTE including PE.

In 2024, Bristol-Myers Squibb and Pfizer launched a digital platform for enhanced patient adherence in DOAC therapy.

In 2025, Boehringer Ingelheim began Phase III trials for a next-generation oral anticoagulant targeting reduced bleeding risks.

Scope of Work – Global Pulmonary Embolism Drug Market

Report Metric Details

Market Size (2023) USD 1.3 billion

Projected Market Size (2031) USD 2.6 billion

CAGR (2023–2031) 9.2%

Key Segments Drug Class (DOACs, Heparin, Thrombolytics), End-Use (Hospitals, ASCs, Homecare), Region

Growth Drivers Rising PE prevalence, Preference for DOACs, Diagnostic and treatment innovations

Opportunities Expansion in emerging markets, Personalized medicine, Outpatient PE management

Key Market Developments:

Bayer AG extended rivaroxaban’s indication to include stroke prevention in atrial fibrillation patients with PE risk.

Pfizer and BMS introduced adherence tools leveraging AI for better DOAC compliance.

Sanofi acquired a biotech startup focusing on thrombolytic drug delivery platforms in 2024 to enhance its PE drug pipeline.

FAQs:

1) What is the current market size of the Global Pulmonary Embolism Drug Market?

The market was valued at USD 1.3 billion in 2023.

2) What is the major growth driver of the Global Pulmonary Embolism Drug Market?

The market is driven by the increasing prevalence of PE and the rising adoption of DOACs for improved treatment outcomes.

3) Which is the largest region during the forecast period in the Global Pulmonary Embolism Drug Market?

North America dominates the market, but Asia-Pacific is expected to record the fastest growth.

4) Which segment accounted for the largest market share in the Global Pulmonary Embolism Drug Market?

The DOACs segment led the market in 2023 due to convenience and safety over traditional therapies.

5) Who are the key market players in the Global Pulmonary Embolism Drug Market?

Key players include Bayer AG, Pfizer Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Johnson & Johnson, Sanofi, and Daiichi Sankyo.

Let me know if you’d like this tailored into a PDF or formatted for slide presentation use as well.